Drug Profile
Research programme: osteoporosis therapeutics - Evotec SE/Nuvios
Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Radius
- Developer Evotec SE; Radius Health Inc.
- Class Small molecules
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 22 Feb 2010 Discontinued - Preclinical for Osteoporosis in United Kingdom (unspecified route)
- 22 Feb 2010 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
- 15 Dec 2005 Nuvios is now called Radius Health